MAIA Biotechnology (MAIA) announced the publication of preclinical data from its second-generation ateganosine prodrugs platform in the journal Nucleic Acids Research. The study details MAIA’s lead ateganosine-derived second-generation prodrugs as promising new molecules for enhancing cancer treatment. The data showed that the sequential combination of its lead compounds with an immune checkpoint inhibitor demonstrated superior anticancer efficacy compared to monotherapies. The company is working to advance at least one candidate into human clinical trials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA: